GSG1L

Across TCGA pan-cancer cohorts, GSG1L Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GSG1L data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher GSG1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GSG1L expression acts as an unfavorable survival marker.

OV, ESCA, and LIHC are the cancer types where GSG1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.046	0.846	<.001	36	view →
ESCA	OS	Median	II,III,IV	0.168	0.707	<.001	30	view →
LIHC	DFS	Median	All	0.157	0.546	.002	12	view →
LUAD	OS	Median	II,III,IV	0.158	0.750	<.001	12	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GSG1L–OV (OS)

Open the OV breakdown →